Search research articles
Contact Us
Filters
Showing results (561-570 of 625) with videos related to
Page
of 63
Sort By:
The American Journal of Tropical Medicine and Hygiene
|
July 4, 2020
Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia
Timothy P Finn, Joshua O Yukich, Adam Bennett, et al.
British Journal of Clinical Pharmacology
|
February 24, 2022
Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: A prospective study in a tertiary-referral hypertension clinic
James M G Curneen, Louise Rabbitt, Darragh Browne, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
The American Journal of Tropical Medicine and Hygiene
|
July 4, 2020
Cost-Effectiveness of Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine for Malaria Prevention in Southern Province, Zambia: Results of a Community-Randomized Controlled Trial
Joshua O Yukich, Callie Scott, Kafula Silumbe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 22, 2024
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation
S Peters, S Loi, F André, et al.
Diagnostics (Basel, Switzerland)
|
October 27, 2022
Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in <i>EGFR</i>-Mutated NSCLC
Martin P Barr, Anne-Marie Baird, Sophia Halliday, et al.
Cancer Cell
|
June 15, 2007
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN
Igor Vivanco, Nicolaos Palaskas, Chris Tran, et al.
Oncotarget
|
October 27, 2017
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
Lauren MacDonagh, Michael F Gallagher, Brendan Ffrench, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
The Contribution of Baseline Circulating Endocannabinoids to Individual Differences in Human Pain Sensitivity: A Quantitative Sensory Testing Study
S A Fatemi, S S Abssy, S L Bourke, et al.
Translational Lung Cancer Research
|
May 20, 2021
MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer
Lauren MacDonagh, Michael F Gallagher, Brendan Ffrench, et al.
Page
of 63
Search research articles
Search
Showing results (561-570 of 625) with videos related to
Sort By:
Page
of 63
The American Journal of Tropical Medicine and Hygiene
|
July 4, 2020
Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia
Timothy P Finn, Joshua O Yukich, Adam Bennett, et al.
British Journal of Clinical Pharmacology
|
February 24, 2022
Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: A prospective study in a tertiary-referral hypertension clinic
James M G Curneen, Louise Rabbitt, Darragh Browne, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
The American Journal of Tropical Medicine and Hygiene
|
July 4, 2020
Cost-Effectiveness of Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine for Malaria Prevention in Southern Province, Zambia: Results of a Community-Randomized Controlled Trial
Joshua O Yukich, Callie Scott, Kafula Silumbe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 22, 2024
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation
S Peters, S Loi, F André, et al.
Diagnostics (Basel, Switzerland)
|
October 27, 2022
Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in <i>EGFR</i>-Mutated NSCLC
Martin P Barr, Anne-Marie Baird, Sophia Halliday, et al.
Cancer Cell
|
June 15, 2007
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN
Igor Vivanco, Nicolaos Palaskas, Chris Tran, et al.
Oncotarget
|
October 27, 2017
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
Lauren MacDonagh, Michael F Gallagher, Brendan Ffrench, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
The Contribution of Baseline Circulating Endocannabinoids to Individual Differences in Human Pain Sensitivity: A Quantitative Sensory Testing Study
S A Fatemi, S S Abssy, S L Bourke, et al.
Translational Lung Cancer Research
|
May 20, 2021
MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer
Lauren MacDonagh, Michael F Gallagher, Brendan Ffrench, et al.
Page
of 63